Evidence map›Paper›PMID 35525870›Full record

ArticleSignal transduction and targeted therapy2022

Omicron: increased transmissibility and decreased pathogenicity.

Gábor Bálint, Barbara Vörös-Horváth, Aleksandar Széchenyi

Abstract readComment
In one paragraph

Article in Signal transduction and targeted therapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 121 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
121citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

121 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Clinical outcomes of the severe acute respiratory syndrome coronavirus 2 Omicron and Delta variant: systematic review and meta-analysis of 33 studies covering 6 037 144 coronavirus disease 2019-positive patients.Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases · 2023
    Pooled it
  4. Trial
  5. Article
  6. Article
  7. Article
  8. Article
  9. Frontiers in immunology · 2026
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

61 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors.

Gábor Bálint *Institute of Pharmaceutical Technology and Biopharmacy, University of Pécs, Faculty of Pharmacy, 7624 Pécs, Rókus u. 2, Pécs, Hungary.
Barbara Vörös-Horváth *Institute of Pharmaceutical Technology and Biopharmacy, University of Pécs, Faculty of Pharmacy, 7624 Pécs, Rókus u. 2, Pécs, Hungary.
Aleksandar SzéchenyiInstitute of Pharmaceutical Technology and Biopharmacy, University of Pécs, Faculty of Pharmacy, 7624 Pécs, Rókus u. 2, Pécs, Hungary. szechenyi.aleksandar@gytk.pte.hu.ORCID 0000-0001-9207-2551

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

COVID-19SARS-CoV-2HumansVirulence

Identifiers

PMID35525870
PMCPMC9077027

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.